Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 3, 2009, Pages

  Zhou, Ming Sheng ^a   Schulman, Ivonne Hernandez ^a   Raij, Leopoldo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelial function; Salt sensitivity

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CANDESARTAN; GLUCOSE; INSULIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SODIUM CHLORIDE; SUPEROXIDE; TEMPOL; AMINE OXIDE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BENZIMIDAZOLE DERIVATIVE; C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, RAT; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE INFUSION; HIGH SODIUM INTAKE; HYPERTENSION; INSULIN RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SALT INTAKE; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR RESISTANCE; VASODILATATION; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; DAHL SALT SENSITIVE RAT; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; SPIN LABELING; VASCULAR ENDOTHELIUM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACETYLCHOLINE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIOXIDANTS; BENZIMIDAZOLES; BLOOD PRESSURE; BODY WEIGHT; C-REACTIVE PROTEIN; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HYPERTENSION; INSULIN; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED DAHL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA, MESSENGER; SIGNAL TRANSDUCTION; SODIUM CHLORIDE, DIETARY; SPIN LABELS; SUPEROXIDE DISMUTASE; TETRAZOLES; VASODILATION; VASODILATOR AGENTS;

EID: 64049097376     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01096.2008     Document Type: Article

References (47)

1. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-convert- ing enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46: 821-826, 2005.
2. 307. J Biol Chem 275: 9047-9054, 2000.
3. Aksnes TA, Kjeldsen SE, Mancia G. The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines? Am J Cardiovasc Drugs 6: 139-147, 2006.
4. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 54: 3458-3465, 2005.
5. Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry 41: 12995-13002, 2002.
6. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR. Renin-angiotensin-aldosterone system and oxida- tive stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293: H2009-H2023, 2007.
7. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipana- watr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105: 311-320, 2000.
8. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111: 1448-1454, 2005.
9. 8a.DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial. Diabetes Care 31: 1007-1014, 2008.
10. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 317: 350-357, 1987.
11. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels-a potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100: 2158-2169, 1997.
12. Fuenmayor N, Moreira E, Cubeddu LX. Salt sensitivity is associated with insulin resistance in essential hypertension. Am J Hypertens 11: 397-402, 1998.
13. Galletti F, Strazzullo P, Ferrara I, Annuzzi G, Rivellese AA, Gatto S, Mancini M. NaCl sensitivity of essential hypertensive patients is related to insulin resistance. J Hypertens 15: 1485-1491, 1997.
14. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28: 2261-2266, 2005.
15. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 420: 333-336, 2002.
16. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23: 463-473, 2005.
17. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 104: 447-457, 1999.
18. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113: 1888 -1904, 2006.
19. Kobayashi T, Taguchi K, Yasuhiro T, Matsumoto T, Kamata K. Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 44: 956 -962,2004.
20. Kotchen TA, Zhang HY, Covelli M, Blehschmidt N. Insulin resistance and blood pressure in Dahl rats and in one-kidney, one-clip hypertensive rats. Am J Physiol Endocrinol Metab 261: E692-E697, 1991.
21. Malik S, Wong ND, Franklin SS, Kamath TV, L'ltalien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110: 1245-1250, 2004.
22. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 24: 3-10, 2006.
23. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 23: 1777-1781, 2005.
24. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 28: 463-491, 2007.
25. 1 receptor regulation. Circulation 105: 530 -536, 2002.
26. Ogihara T, Asano T, Katagiri H, Sakoda H, Anai M, Shojima N, Ono H, Fujishiro M, Kushiyama A, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Gotoh Y, Komuro I, Fujita T. Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-ki- nase. Diabetologia 47: 794-805, 2004.
27. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 110: 1507-1512,
28. 2004.
29. Pritchett AM, Foreyt JP, Mann DL. Treatment of the metabolic syndrome: the impact of lifestyle modification. Curr Atheroscler Rep 7: 95-102, 2005.
30. Raij L. Hypertension and cardiovascular risk factors-role of the angio- tensin II-nitric oxide interaction. Hypertension 37: 767-773, 2001.
31. Schulman IH, Zhou MS, Jaimes EA, Raij L. Dissociation between metabolic and vascular insulin resistance in aging. Am J Physiol Heart Circ Physiol 293: H853-H859, 2007.
32. Sechi LA, Griffin CA, Zingaro L, Catena C, De Carli S, Schambelan M, Bartoli E. Glucose metabolism and insulin receptor binding and mRNA levels in tissues of Dahl hypertensive rats. Am J Hypertens 10: 1223-1230, 1997.
33. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 43: 255-262, 2004.
34. Somova L, Channa ML. Glucose metabolism and insulin sensitivity in Dahl hypertensive rats. Methods Find Exp Clin Pharmacol 21: 421-425, 1999.
35. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286: H1597-H1602, 2004.
36. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin- mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94: 1172-1179, 1994.
37. Stump CS, Henriksen EJ, Wei Y, Sowers JR. The metabolic syndrome: role of skeletal muscle metabolism. Ann Med 38: 389-402, 2006.
38. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, Morris EM, Szary N, Manrique C, Stump CS. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 281: 35137-35146, 2006.
39. Wei Y, Whaley-Connell AT, Chen K, Habibi J, Uptergrove GM, Clark SE, Stump CS, Ferrario CM, Sowers JR. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 50: 384-391, 2007.
40. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension 18: 67-71, 1991
41. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 37: 429-432, 2001.
42. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119, 2005.
43. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539 -1545, 2000.
44. Zhou MS, Adam AG, Jaimes EA, Raij L. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 42: 945-951, 2003.
45. Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angio- tensin II, atherogenesis, and blood pressure. Hypertension 47: 81-86, 2006.
46. Zhou MS, Kosaka H, Tian RX, Abe Y, Chen QH, Yoneyama H, Yamamoto A, Zhang L. L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats. J Hypertens 19: 421-429, 2001.
47. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endo- thelial function, and vascular oxidative stress. J Hypertens 26: 494 -500, 2008.